Dr. Reddy's Laboratories LimitedRDYNYSE
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
-0.67%
↓ 100% below average
Average (39q)
1512.20%
Historical baseline
Range
High:8346.59%
Low:-98.68%
CAGR
-6.3%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | -0.67% |
| Q2 2025 | -13.97% |
| Q1 2025 | 9.01% |
| Q4 2024 | -8.43% |
| Q3 2024 | 17.41% |
| Q2 2024 | -9.95% |
| Q1 2024 | 23.58% |
| Q4 2023 | 8346.59% |
| Q3 2023 | -98.68% |
| Q2 2023 | 7539.20% |
| Q1 2023 | -98.65% |
| Q4 2022 | 7802.13% |
| Q3 2022 | -98.59% |
| Q2 2022 | 7422.34% |
| Q1 2022 | -98.62% |
| Q4 2021 | 6804.41% |
| Q3 2021 | -98.67% |
| Q2 2021 | 7972.74% |
| Q1 2021 | -98.63% |
| Q4 2020 | 7372.00% |
| Q3 2020 | -98.62% |
| Q2 2020 | -5.01% |
| Q1 2020 | 8019.06% |
| Q4 2019 | -98.59% |
| Q3 2019 | 1.47% |
| Q2 2019 | -1.45% |
| Q1 2019 | -0.16% |
| Q4 2018 | -10.97% |
| Q3 2018 | -0.89% |
| Q2 2018 | -4.39% |
| Q1 2018 | -6.84% |
| Q4 2017 | 11.78% |
| Q3 2017 | -17.73% |
| Q2 2017 | 10.83% |
| Q1 2017 | -7.61% |
| Q4 2016 | -4.95% |
| Q3 2016 | 8.58% |
| Q2 2016 | -1.58% |
| Q1 2016 | 19.15% |
| Q4 2015 | -8.45% |